Evaluation of the Efficacy and Safety of Anifrolumab in Moderate-to-Severe Systemic Lupus Erythematosus
AR Cingireddy, N Ramini, AR Cingireddy - Cureus, 2024 - pmc.ncbi.nlm.nih.gov
Systemic lupus erythematosus (SLE) is an autoimmune disease, which poses significant
challenges due to its chronic nature and complex clinical manifestations. For patients with …
challenges due to its chronic nature and complex clinical manifestations. For patients with …
[HTML][HTML] Clinical Trials of Interferon Inhibitors in Systemic Lupus Erythematosus and Preliminary Real-World Efficacy of Anifrolumab
S Díaz-Planellas, D Katsifis-Nezis… - Mediterranean …, 2024 - pmc.ncbi.nlm.nih.gov
Approval of anifrolumab for the treatment of moderate-to-severe systemic lupus
erythematosus (SLE) in 2021 marked the success of a long quest to target the interferon …
erythematosus (SLE) in 2021 marked the success of a long quest to target the interferon …
Treatment of discoid lupus with lenalidomide and anifrolumab: Case report and review of the literature
CS Centner, NM Robertson, J Kang, IB Sander… - Lupus, 2024 - journals.sagepub.com
Discoid lupus erythematosus (DLE) is a devastating autoimmune disease with few therapies
available. For patients with little to no symptom improvement with initial treatment, the …
available. For patients with little to no symptom improvement with initial treatment, the …
Cutaneous lupus erythematosus: a review of new and emerging therapies.
J Xará, M Gonçalo - Portuguese Journal of Dermatology & …, 2024 - search.ebscohost.com
Cutaneous lupus erythematosus (CLE) is an autoimmune connective tissue disorder with
heterogenous skin manifestations. According to the current therapeutic guidelines for the …
heterogenous skin manifestations. According to the current therapeutic guidelines for the …